FDA Update Puts Hims And Hers Weight Loss Partnerships In Focus

Simply Wall St.04-28 09:16

Regulators are scheduled to meet in July to discuss FDA guidance that could influence how NYSE:HIMS expands its weight-loss and wellness portfolio beyond standard GLP-1 therapies. Hims & Hers Health ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2630347575?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566","is_english":true,"pubTime":"2026-04-28 09:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630347575","market":"nz","top_or_hot":-1,"title":"FDA Update Puts Hims And Hers Weight Loss Partnerships In Focus","media":"Simply Wall St.","content":"<div>\n<p>Regulators are scheduled to meet in July to discuss FDA guidance that could influence how NYSE:HIMS expands its weight-loss and wellness portfolio beyond standard GLP-1 therapies. Hims & Hers Health ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-hims/hims-hers-health/news/fda-update-puts-hims-and-hers-weight-loss-partnerships-in-fo\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Update Puts Hims And Hers Weight Loss Partnerships In Focus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Update Puts Hims And Hers Weight Loss Partnerships In Focus\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-28 09:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-hims/hims-hers-health/news/fda-update-puts-hims-and-hers-weight-loss-partnerships-in-fo><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Regulators are scheduled to meet in July to discuss FDA guidance that could influence how NYSE:HIMS expands its weight-loss and wellness portfolio beyond standard GLP-1 therapies. Hims & Hers Health ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-hims/hims-hers-health/news/fda-update-puts-hims-and-hers-weight-loss-partnerships-in-fo\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-hims/hims-hers-health/news/fda-update-puts-hims-and-hers-weight-loss-partnerships-in-fo","article_id":"2630347575","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-hims/hims-hers-health/news/fda-update-puts-hims-and-hers-weight-loss-partnerships-in-fo","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2630347575","pubTimestamp":1777338973,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Regulators are scheduled to meet in July to discuss FDA guidance that could influence how NYSE:HIMS expands its weight-loss and wellness portfolio beyond standard GLP-1 therapies.\nHims & Hers Health is receiving fresh attention from large institutions, including new analyst coverage focused on its role in highly topical weight-loss therapeutics.\nPartnerships with Eli Lilly and Novo Nordisk are drawing interest as investors assess how these relationships might shape the company’s long-term...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","HMYY":"GraniteShares YieldBoost HIMS ETF","BK4196":"保健护理服务","HIMS":"Hims & Hers Health Inc.","HIYY":"YieldMax HIMS Option Income Strategy ETF","HIMY":"Defiance Leveraged Long + Income HIMS ETF","BK4588":"碎股","HIMZ":"DEFIANCE DAILY TARGET 2X LONG HIMS ETF"},"translate_title":"FDA更新使他和她的减肥合作伙伴关系成为焦点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMZ":0.6,"HIYY":0.6,"HIMS":1.98,"HMYY":0.6,"HIMY":0.6},"content_text":"Regulators are scheduled to meet in July to discuss FDA guidance that could influence how NYSE:HIMS expands its weight-loss and wellness portfolio beyond standard GLP-1 therapies. Hims & Hers Health is receiving fresh attention from large institutions, including new analyst coverage focused on its role in highly topical weight-loss therapeutics. Partnerships with Eli Lilly and Novo Nordisk are drawing interest as investors assess how these relationships might shape the company’s long-term product mix.  Hims & Hers Health, listed as NYSE:HIMS, operates a direct to consumer platform focused on personal wellness, including weight management, mental health, and other everyday health categories. As GLP-1s and related weight-loss treatments stay in the spotlight, the upcoming FDA meeting in July sits at the center of discussions about how far the company can extend its current offerings. For investors, this places regulatory decisions alongside product and distribution questions rather than just marketing or branding. Looking ahead, the key issue is how any FDA clarity interacts with Hims & Hers Health’s partnerships with Eli Lilly and Novo Nordisk and its existing telehealth model. If the meeting sets clearer boundaries for prescribing and monitoring next generation weight-loss drugs, that could influence which therapies NYSE:HIMS features on its platform, how it structures patient programs, and which parts of the wellness category it prioritizes over time. Stay updated on the most important news stories for Hims & Hers Health by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Hims & Hers Health. NYSE:HIMS Earnings & Revenue Growth as at Apr 2026 📰 Beyond the headline: 3 risks and 3 things going right for Hims & Hers Health that every investor should see. AdvertisementQuick Assessment  ⚖️ Price vs Analyst Target: At US$29.39, Hims & Hers Health trades about 15% above the consensus price target of US$25.57, with analysts split between US$16 and US$35. ✅ Simply Wall St Valuation: Simply Wall St estimates the shares are trading 51.9% below fair value, suggesting a wide gap between its model and the market price. ✅ Recent Momentum: The 30 day return of 0.52% shows modest positive momentum heading into the FDA update.  There is only one way to know the right time to buy, sell or hold Hims & Hers Health. Head to the Simply Wall St\ncompany report for the latest analysis of Hims & Hers Health's Fair Value. Key Considerations  📊 The potential for FDA clarity on weight-loss treatments could be an important factor for how much value investors ascribe to the Eli Lilly and Novo Nordisk partnerships. 📊 Watch how pricing, prescription volumes and product mix in GLP-1 and next generation therapies evolve once any new guidance is released. ⚠️ The shares have been highly volatile over the past three months, so regulatory headlines could trigger sharp short term price moves.  Dig Deeper For the full picture including more risks and rewards, check out the\ncomplete Hims & Hers Health analysis. Alternatively, you can visit the\ncommunity page for Hims & Hers Health to see how other investors believe this latest news will impact the company's narrative.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Hims &amp; Hers Health might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2630347575","isCrawlerRequest":true}